GILDKite, A Gilead CompanyRunning, no new patients
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Relapsed or Refractory Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 550 (planned)
- Started
- May 22, 2026
- Main results expected
- May 2031
- Fully finished
- May 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of Participants in Complete Response (CR) at Month 6
Measured over: Month 6
Event-free survival (EFS)
Measured over: Up to 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07479797 · record last updated 2026-10-26 · checked 2026-11-09 15:47 UTC